Potential Liver Problems Halt Alzheimer's Drug Study

Friday, 14 Jun 2013 08:13 AM

 

  Comment  |
   Contact  |
  Print  
|  A   A  
  Copy Shortlink
Eli Lilly and Co. said on Thursday it halted a mid-stage study of an experimental Alzheimer's disease treatment due to potential liver toxicity, the latest setback in the quest to find a treatment that can slow or cure the memory-robbing condition.
 
Lilly said the Phase II study of the drug, LY2886721, from a class known as beta secretase, or BACE, inhibitors, was stopped after safety monitors identified cases of abnormal liver tests.
 
The Indianapolis-based drugmaker said the liver issues do not appear related to the drug's mechanism, and that it remains interested in developing BACE inhibitors to treat the progressive brain disease.
 
Oral drugs to block beta secretase, although still unproven, have been one of the biggest hopes for slowing progression of the disease after another class of medicines being developed by Lilly and Pfizer Inc. last summer fell short in big trials.
 
Those injectable drugs, Lilly's solanezumab and Pfizer's bapineuzumab, directly block beta-amyloid, a protein that forms brain plaques considered a prime cause of Alzheimer's disease.
 
Solanezumab failed to slow progression of Alzheimer's among patients with mild to moderate disease. It is now being tested in patients with mild disease because it was shown to slow loss of memory in that narrower population. Bapineuzumab has been largely written off by investors after failing to slow progression of Alzheimer's in its late-stage trials.
 
BACE inhibitors, including rival products being developed by Merck & Co., Roche Holding AG and Eisai Co. Ltd, are meant to prevent buildup of beta-amyloid by blocking an enzyme called BACE1.
 
Industry analysts have said any of the BACE inhibitors could become huge sellers, with annual sales of $3 billion or more, if they prove effective and are approved. That is because no drugs currently slow progression of Alzheimer's, the biggest cause of dementia, which is believed to affect an estimated 5 million Americans.
 
Even so, Wall Street is not assuming the drugs will succeed, because they are in relatively early development and there have been few clues on their safety and effectiveness.
 
An estimated 35 million people worldwide are believed to have dementia, including Alzheimer's disease, and those numbers are expected to rise as more people live longer.
Lilly shares closed up 0.1 percent on Thursday, amid a 1 percent gain for the drug sector.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

FDA Adds Warning Labels to Tanning Devices

Friday, 28 Nov 2014 09:22 AM

Early in 2014, the United States Food and Drug Administration moved tanning lamps into a new category of "moderately har . . .

15-Minute Test for Ebola

Friday, 28 Nov 2014 09:14 AM

A new test designed to rapidly diagnose Ebola virus infection is to be tried out at a treatment center for the disease i . . .

Yoga, Meditation Ease Arthritis Pain: Study

Friday, 28 Nov 2014 09:09 AM

A two-month program combining gentle yoga with meditation techniques,known as Mindfulness Based Stress Reduction, seemed . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved